Catalyst Crew Technologies Corp. has submitted a corporate action request to the Financial Industry Regulatory Authority seeking approval for a proposed name change to LataMed AI Corp. and a corresponding change to its trading symbol. The move aims to better reflect the company's strategic direction following its transition toward artificial intelligence-enabled healthcare technology.
The proposed corporate action was approved by the company's Board of Directors and by written consent of its majority shareholder in accordance with Nevada law. The company emphasized that the proposed action does not involve any reverse stock split, forward stock split, recapitalization, change to authorized capital, or other modification to its capital structure. The issued and outstanding share count will remain unchanged, and the name and symbol change will not affect shareholders' ownership interests, requiring no action from existing shareholders.
Upon FINRA approval, the company intends to file a Certificate of Amendment with the Nevada Secretary of State to effect the corporate name change. The proposed changes would become effective upon completion of required corporate filings and publication by FINRA on the Daily List. Dr. Kevin Rodan Levy, Chief Executive Officer of Catalyst Crew Technologies Corp., stated that the proposed name change is intended to better align the company's public identity with its healthcare technology strategy and long-term market focus.
The company noted that no assurance can be given that FINRA will approve the proposed name change, the requested new trading symbol, or the timing of any such approval. For more information, investors can visit https://catalystcrewai.com or review the company's filings with the U.S. Securities and Exchange Commission at https://www.sec.gov.
This development is significant as it signals a formal corporate rebranding aligned with the company's pivot toward artificial intelligence in healthcare, specifically targeting Latin American markets. The name change to LataMed AI Corp. explicitly communicates this regional and technological focus to investors, partners, and the market at large. For the healthcare technology industry, it represents another player consolidating its identity around AI-driven solutions, potentially increasing competition and innovation in digital health platforms for emerging markets.
The implications extend to investors and stakeholders who now have clearer insight into the company's strategic priorities. By shedding a generic name for one that denotes both geographic focus (Latin America) and technological capability (AI), the company may enhance its market positioning and attract interest from investors specifically looking at AI healthcare opportunities in growing economies. However, the company remains a development-stage enterprise that has not generated revenues from its newly announced business direction, underscoring the speculative nature of such strategic shifts.
For the broader world, this move highlights the ongoing convergence of artificial intelligence and healthcare delivery, particularly in regions with evolving healthcare infrastructure. If successful, the company's focus on telehealth infrastructure, remote patient monitoring, and healthcare data analytics could contribute to improved access and efficiency in Latin American healthcare systems. The corporate rebranding, while administrative in nature, serves as a public milestone in the company's transition and could influence how similar firms articulate their strategic evolutions in the future.
